How to Determine the Classification of Implantable Products for Overseas Registration?

Key Summary

The classification determination for overseas registration of implantable products directly dictates the registration pathway, technical documentation requirements, clinical evaluation depth, and post-market surveillance obligations. Companies should not simply apply NMPA classifications or extrapolate outcomes from a single market such as CE or FDA to other jurisdictions. The correct approach is: first, confirm whether the product falls within the regulatory scope of medical devices in the target country, excluding borderline cases such as drugs, combination products, or human tissue derivatives; second, determine the risk class according to the target country's regulatory definitions and classification rules—for example, the US FDA generally classifies most implants as Class II or Class III, while under the EU MDR most implants are Class III, and GHWP member states each have their own classification lists or risk-based criteria; third, select the registration pathway based on risk class, such as FDA 510(k), PMA, or De Novo, EU MDR notified body conformity assessment, and registration certificate applications in Southeast Asia, the Middle East, and other regions; fourth, assess whether existing technical documentation and system evidence from NMPA, CE, FDA, ISO 13485, MDSAP, etc., can be reused and identify what needs local adaptation. Implantable products require special preparation of biocompatibility data, animal study or clinical trial documentation, sterilization validation, labeling and instructions for use in local languages, and appointment of a local agent or authorized representative. Common risks include incorrect classification leading to submission of the wrong pathway, insufficient clinical evidence, lack of local representative responsibility, and failure to notify post-market changes. Companies should complete a target-country classification pre-assessment and document gap analysis before project start to reduce the burden of corrections and rework.

Organized based on AIMEILI registration practice questions, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product dossier.

Applicable Scenarios and Core Issues

Implantable products are among the highest-risk, most technically complex, and most clinically demanding categories in medical device regulation. When planning exports or overseas registration, the first issue companies face is not how to prepare documents, but how the product will be managed in the target country. If this classification judgment is wrong, all subsequent work may be overturned.

Scenarios covered in this article include orthopedic implants, cardiovascular implants, neurostimulators, aesthetic fillers, and dental implants—both active and passive implantable devices. Companies typically already hold an NMPA registration certificate in China or are applying for NMPA, while simultaneously seeking entry into GHWP member countries, Southeast Asia, the Middle East, Latin America, or Western markets.

The core issue is that different countries have inconsistent definitions and classification logic for 'implantable products.' The same product may be Class III in China, Class II or III in the US, reclassified as Class III under the EU MDR, and may follow EU or US classifications or have its own classification list in Southeast Asian countries.

Companies need to answer several specific questions: Does the product fall within the regulatory scope of medical devices in the target country? What risk class applies under target-country rules? Which registration pathway is appropriate? What technical documentation and clinical evidence are required? Is a local representative needed? What ongoing post-market obligations exist?

These judgments are not a one-time exercise. Classification results may change with product specifications, intended use, material composition, presence of drug components, biodegradability, and other factors. Companies should establish a classification review process to avoid relying solely on experience or conclusions from a single market.

Registration Classification Logic

Step 1: Confirm Device Status

First, confirm whether the product qualifies as a medical device in the target country. Many countries define implants as 'devices that are introduced entirely or partially into the human body through surgery and remain in the body for at least 30 days,' but there are subtle differences in retention time, surgical method, and material origin. If the product has a drug coating, animal-derived material, or human cellular components, it may be classified as a drug, combination product, or biological product.

Step 2: Determine Risk Class

Second, determine the risk class according to the target country's classification rules. The US FDA classifies devices under 21 CFR 862-892; most active implants and some passive implants are Class III, while some items like bone screws and plates may be Class II. Under the EU MDR, classification follows specific rules; most implants are Class III due to Rule 8, with a few exceptions such as implants not contacting the central nervous system potentially being Class IIb. GHWP member states generally use risk-based classification, often assigning implants to the highest or second-highest risk level.

Step 3: Select Registration Pathway

Third, determine the registration pathway. In the US, Class III implants may require PMA, while Class II devices generally require 510(k) with special controls. In the EU, Class III devices require notified body conformity assessment involving clinical evaluation and post-market clinical follow-up. In Southeast Asian countries such as Thailand, the Philippines, Vietnam, and Indonesia, local registration certificates are typically required, but requirements may be simplified based on approval in the country of origin. In Middle Eastern countries such as Saudi Arabia and the UAE, local registration and a local agent are also required.

Step 4: Assess Reusability of Existing Documentation

Fourth, evaluate whether existing documentation can be reused. Companies should create an inventory of NMPA registration certificates, CE technical files, FDA submission materials, ISO 13485 certificates, MDSAP certificates, product test reports, biological evaluation reports, and clinical evaluation reports. If the product is already approved in China, registration testing and quality system audit materials can usually serve as a foundation, but format conversion and risk reassessment will be needed to meet target-country requirements.

Step 5: Identify Localization Requirements

Fifth, identify localization needs. Technical documents cannot simply be translated; they must be adapted to local regulations, clinical practices, disease prevalence, label language, local agent responsibilities, and post-market surveillance requirements. For example, Middle Eastern countries may require halal or culturally appropriate labeling, and Latin American countries require Spanish or Portuguese instructions.

Step 6: Clarity Post-Market Maintenance Responsibilities

Sixth, clarify post-market maintenance responsibilities. In most countries, implantable products require continuous adverse event monitoring, periodic clinical data updates, notification of significant changes, and regulatory authority inspections. Companies must appoint an authorized representative in the target country, who takes on legal responsibilities such as communicating with regulatory authorities, maintaining documents, and receiving inspection notices.

Documentation and Evidence

The direct evidence for classification of implantable products comes from product description, intended use, mechanism of action, materials, duration of body contact, absorbability, and whether drugs are combined. This information forms the first layer of the technical file and is the basis for classification determination.

Companies should prepare a product classification justification document that cites the target country's regulations, classification rules, classification lists, or precedents, and provides classification conclusions with reasons for each market. This document serves as internal decision-making basis and as explanatory material for subsequent registration submissions.

The core documentation checklist includes: product name, model/specification, structural composition, material composition and source; intended use and target population; principle of action and mode of operation; sterile presentation and sterilization method; nature and duration of body contact; presence of drug release or bioactive coating; presence of degradable or absorbable components; and preclinical study data.

If a Chinese NMPA registration certificate exists, provide the certificate, product technical requirements, test reports, clinical trial or exemption documentation. If a CE certificate exists, provide the CE technical file summary and notified body certificate. If FDA approval or 510(k) information exists, provide corresponding documents. These materials can significantly influence target-country classification decisions and review speed.

Risk management files are indispensable. ISO 14971 risk management documentation must cover long-term risks of implants, particulate migration, biocompatibility, surgical complications, and failure modes. Biocompatibility evaluation should comply with ISO 10993 series standards, including chronic toxicity, genotoxicity, implantation, and carcinogenicity tests for implants retained beyond 30 days.

Clinical evaluation is core evidence for implantable products. Companies need to compile published clinical literature, their own clinical trial data, or clinical data on equivalent devices to form a clinical evaluation report compliant with target-country requirements. For high-risk implants, many countries require local clinical trials or acceptance of foreign data with a bridging study.

Labels and instructions for use require separate preparation. Implant labels typically include device name, model, material, size, sterilization method, single-use indication, intended use, target population, surgical precautions, contraindications, and adverse event information. Local language versions must be translated and reviewed by professionals.

A local agent or authorized representative authorization letter is a mandatory document for registration applications. Companies need to sign and notarize the authorization agreement in advance, specifying the scope and duration of the representative's duties. Some countries also require the agent to hold a local medical device business permit or registration.

Common Mistakes

• Directly inferring all overseas markets are highest risk based on NMPA Class III, leading to selection of an overly burdensome registration pathway, wasting time and money.
• Ignoring differences in the target country's definition of 'implant,' such as confusing a 30-day retention period with permanent implantation or incorrectly declaring drug-coated products as pure devices.
• Copying CE classification conclusions to the US or Southeast Asia; FDA classification requires review of 21 CFR, and some products that are Class III under CE may be eligible for 510(k) in the US.
• Failing to prepare a classification justification document, providing only verbal conclusions, and lacking a basis to explain classification during regulatory review.
• Insufficient clinical evidence—relying only on literature reviews without adequate analysis of product differences, resulting in requests for supplemental clinical trials or data.
• Ignoring the contact duration correlation in biocompatibility testing—using short-term test protocols for long-term contact implants.
• Inadequate localization of labels and instructions—translation errors, incorrect units of measure, or missing warning statements required by local regulations.
• Failing to appoint a local agent or failing to appoint in time, causing registration applications to be rejected or certificates to lapse.
• Neglecting post-registration change notification obligations—material, design, or sterilization method changes without submitting change applications to regulatory authorities, triggering compliance risks.

Company Preparation Checklist

• Compile all technical parameters of the product, create a bilingual (Chinese-English) product description table, and clarify intended use and contact duration.
• Check the official website or database of the target country's regulatory authority to confirm product classification, registration pathway, and fees.
• Establish a cross-market classification comparison table, recording classification results from China NMPA, EU MDR, US FDA, and GHWP member states.
• Inventory existing certificates and reports, including NMPA registration certificate, CE certificate, FDA 510(k), ISO 13485, MDSAP, and test reports.
• Write a classification justification document and a statement of submission intent for explanation during review.
• Assess clinical data gaps and develop a plan for supplemental clinical evaluation or clinical trials.
• Update risk management reports and biocompatibility evaluation documents to ensure all tests required by the target country are covered.
• Appoint a local agent or authorized representative and sign an agreement specifying change notification and renewal responsibilities.
• Create multilingual labels and instructions, and have them reviewed by professional language service providers.
• Develop a post-market surveillance plan, including adverse event reporting, periodic risk updates, and clinical follow-up.

AIMEILI Perspective

The most common mistake companies make is not classification itself, but treating classification as a static conclusion. Implantable products in overseas registration often require repeated classification judgments because each country's regulatory basis differs. We recommend abandoning the mindset of 'one classification for all markets' and instead establishing a classification matrix at project launch.

The first thing to do at the project outset is to spend two to three weeks on a target-country regulatory gap analysis, rather than directly translating documents. Classification is the cornerstone of a registration strategy; if the cornerstone is misaligned, subsequent submissions may be rejected or incur high correction costs. Even with a tight budget, the classification justification document deserves priority investment.

Regarding document reuse, NMPA registration certificates, ISO 13485 certificates, MDSAP certificates, product test reports, and risk management documents are generally reusable, but need updated formatting and context. Biocompatibility reports can be reused, but it is necessary to confirm testing standards and acceptance in the target country. Clinical evaluation is the hardest to reuse directly—especially when the target country requires local population data or epidemiological context, a localization analysis is mandatory.

Local agents, certificate control rights, changes, and renewals are blind spots for many companies. A local agent is more than a signatory; they are the sole legal channel for regulatory agencies to contact the company. Companies must ensure the agent's qualifications are genuine and agree from the start that certificates are controlled by the company, avoiding certificate invalidation due to an agent's departure or termination. Change and renewal cycles are often longer than initial registration, so companies should maintain a validity calendar and start preparation at least twelve months in advance.

For multi-country registration, we recommend a 'one core, multiple statements' strategy: use one set of core technical documents as a base and derive localized versions according to each target country's requirements. This reduces duplicate work and avoids data contradictions caused by submitting different versions across markets. Companies should also assign dedicated personnel to monitor regulatory changes and update internal strategies when classification rules, guidance documents, or fee schedules are adjusted.

AIMEILI's perspective does not encourage using techniques to circumvent regulations, but rather improving efficiency within a compliant framework. Implantable products carry high risk and long lifecycles; doing classification and gap analysis well in the early stages earns the initiative for subsequent registration, market entry, and maintenance.

Frequently Asked Questions

Are all implantable products under the EU MDR classified as Class III?

Not all. Under the EU MDR classification rules, Rule 8 states that implantable devices and absorbable implants are generally Class III, but some specific exceptions may be classified as Class IIb, such as certain implants used for temporary support. Companies should assess based on the product's intended use and MDR rules, rather than simply assuming 'implant equals Class III.'

If a product has received FDA 510(k) clearance in the US, can that classification be directly used for other countries?

No, it cannot be directly applied. FDA 510(k) clearance only indicates that the device is substantially equivalent to a legally marketed predicate device; it does not mean other regulatory authorities will accept the same classification. Many countries refer to FDA classifications, but they all have their own regulations and exceptions. It is recommended to use FDA documents as one piece of evidence, but still judge independently under each target country's rules.

How much help are NMPA Class III implant files for CE marking?

They are very helpful but not sufficient. NMPA registration test data, biological evaluation, clinical trial data, and quality management system documents can serve as a basis for the CE technical file, but they need to be converted into the structure and format required by CE regulations. In particular, the clinical evaluation section under MDR has higher requirements for clinical evidence sufficiency and post-market clinical follow-up; submitting NMPA clinical trial data alone is usually not enough.

Does a biodegradable implant have a different classification?

Biodegradable implants are generally considered higher risk, but the specific classification still depends on material, degradation products, and intended use. Many countries assign biodegradable implants to the highest risk category because degradation products may cause long-term toxicity or local reactions, requiring more complete studies of degradation mechanisms and metabolism.

Will the absence of a local agent affect a registration application?

Yes, it directly affects it. Most countries require an applicant to have a local agent or authorized representative responsible for contacting regulatory authorities, receiving inspection notices, and handling adverse event reports. Without a local agent, the registration application is typically not accepted. It is recommended to complete the agency agreement and notarized authorization before submission.

Continue Reading

• Previous article: Rehabilitation Equipment Overseas Registration: What to Do When Quality System Certificates Are Inconsistent?
• Next article: How to Organize Technical Files for Overseas Registration of Implantable Products?
• Recommended reading: Rehabilitation Equipment Overseas Registration: How to Perform Post-Market Surveillance?
• Rehabilitation Equipment Overseas Registration: When Should Registration Changes Be Notified?
• Rehabilitation Equipment Overseas Registration: What to Prepare Before Renewal?
• Rehabilitation Equipment Overseas Registration: What to Do When Quality System Certificates Are Inconsistent?
• How to Organize Technical Files for Overseas Registration of Implantable Products?
• Imaging Equipment Overseas Registration: How Are Authorized Representative Responsibilities Divided?

Return to FAQ Center

News & Updates | Contact AIMEILI

Content Review and Applicability

Author: AIMEILI Regulatory Editorial Department

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used as supplementary references.

Applicability: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace formal requirements from target-country regulatory authorities, test conclusions, or legal advice.